Net revenue of MannKind Corp.’s flagship drug, Afrezza, jumped 58 percent to $8 million compared to $5.1 million in last year’s first financial quarter, the company said in its earnings report on Wednesday...

Join our Membership to get the full story.


Are you a current Member? Sign In